Elizabeth Fox

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. doi request reprint Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma
    Elizabeth Fox
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 19:4239-48. 2013
  2. ncbi request reprint Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321-e329. 2012
  3. pmc Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321. 2012
  4. pmc The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA 19104, USA
    J Neuroimmunol 223:138-40. 2010
  5. pmc A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology CTRB4016, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Oncol 28:5174-81. 2010
  6. pmc Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors
    Robin E Norris
    Division of Pediatric Hematology Oncology, Rainbow Babies and Children s Hospital, Cleveland, Ohio Division of Clinical Pharmacology and Therapeutics, Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:145-50. 2014
  7. doi request reprint Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study
    Rochelle Bagatell
    The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:833-9. 2014
  8. doi request reprint Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 18:6058-64. 2012

Collaborators

Detail Information

Publications8

  1. doi request reprint Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma
    Elizabeth Fox
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 19:4239-48. 2013
    ..Vandetanib, a VEGF and EGF receptor inhibitor, blocks RET tyrosine kinase activity and is active in adults with hereditary MTC...
  2. ncbi request reprint Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321-e329. 2012
    ..The rate of enrollment, rather than the statistical design, had a significant effect on the trial duration...
  3. pmc Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321. 2012
    ..The primary objective was to determine the objective response rate using response evaluation criteria in solid tumors (RECIST)...
  4. pmc The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA 19104, USA
    J Neuroimmunol 223:138-40. 2010
    ..8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra. The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range...
  5. pmc A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology CTRB4016, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Oncol 28:5174-81. 2010
    ....
  6. pmc Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors
    Robin E Norris
    Division of Pediatric Hematology Oncology, Rainbow Babies and Children s Hospital, Cleveland, Ohio Division of Clinical Pharmacology and Therapeutics, Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:145-50. 2014
    ..We evaluated the PARP inhibitor, olaparib, in combination with chemotherapy using in vitro and in vivo pediatric solid tumor models...
  7. doi request reprint Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study
    Rochelle Bagatell
    The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:833-9. 2014
    ..A phase I trial of the mTOR inhibitor temsirolimus (TEM) with irinotecan (IRN) and temozolomide (TMZ) was conducted in children with recurrent/refractory solid tumors, including central nervous system (CNS) tumors...
  8. doi request reprint Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 18:6058-64. 2012
    ..We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic properties of MLN8237...